'Triple Negative Breast Cancer Conference 2013', London, UK
26 June 2013 - 26 June 2013
United Kingdom
The 'Triple Negative Breast Cancer Conference 2013' will be held from 26 to 28 June 2013 in London, UK.
High quality research, early and accurate diagnosis in addition to optimised targeted treatment is essential in caring for those affected by cancer. Research into improving the limited treatment options and prognosis of patients with triple negative breast cancer has seen breakthroughs in recent years though much remains to be discovered to provide patients with improved outcomes in the future.
This conference aims to offer a comprehensive insight into the challenges, controversies and developments of triple negative breast cancer research. Topics of discussion include the mutational development of breast cancer, molecular classification of triple negative breast cancer and pathology of immune cell infiltration.
The three-day event will inform participants of the etiology, diagnosis and treatment of this challenging disease through a series of plenary sessions and workshops. Participants can expect to find out the latest clinical trial results and share their expertise with multi-disciplinary colleagues.For further information, please visit:
http://www.breakthroughconference.org.uk/index.htm(opens in new window)
High quality research, early and accurate diagnosis in addition to optimised targeted treatment is essential in caring for those affected by cancer. Research into improving the limited treatment options and prognosis of patients with triple negative breast cancer has seen breakthroughs in recent years though much remains to be discovered to provide patients with improved outcomes in the future.
This conference aims to offer a comprehensive insight into the challenges, controversies and developments of triple negative breast cancer research. Topics of discussion include the mutational development of breast cancer, molecular classification of triple negative breast cancer and pathology of immune cell infiltration.
The three-day event will inform participants of the etiology, diagnosis and treatment of this challenging disease through a series of plenary sessions and workshops. Participants can expect to find out the latest clinical trial results and share their expertise with multi-disciplinary colleagues.For further information, please visit:
http://www.breakthroughconference.org.uk/index.htm(opens in new window)